Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Biodesix (BDSX) over the last 4 years, with Q3 2025 value amounting to $35000.0.

  • Biodesix's Gains from Sales and Divestitures rose 165000.0% to $35000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35000.0, marking a year-over-year increase of 165000.0%. This contributed to the annual value of $613000.0 for FY2024, which is 1366.2% down from last year.
  • Latest data reveals that Biodesix reported Gains from Sales and Divestitures of $35000.0 as of Q3 2025, which was up 165000.0% from $627000.0 recorded in Q2 2025.
  • In the past 5 years, Biodesix's Gains from Sales and Divestitures ranged from a high of $710000.0 in Q4 2023 and a low of $2000.0 during Q3 2024
  • In the last 4 years, Biodesix's Gains from Sales and Divestitures had a median value of $256500.0 in 2022 and averaged $306714.3.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first crashed by 9740.26% in 2024, then surged by 165000.0% in 2025.
  • Biodesix's Gains from Sales and Divestitures (Quarter) stood at $357000.0 in 2022, then surged by 98.88% to $710000.0 in 2023, then dropped by 13.66% to $613000.0 in 2024, then plummeted by 94.29% to $35000.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $35000.0 for Q3 2025, versus $627000.0 for Q2 2025 and $486000.0 for Q1 2025.